Replies to post #56619 on Biotech Values

[rkrw]

I don't think fragmin is going anywhere, the upside doesn't justify the investment since fragmin is only a modest seller.

178 and 249 are undisclosed royalties, so hard to say what they're worth.

Lovenox (if not one of many), copaxone and 118 success certainly would justify the share price and more.